C4 Therapeutics (CCCC) Stock Overview
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CCCC Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
C4 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.95 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.09 |
| Beta | 2.94 |
| 1 Month Change | 55.26% |
| 3 Month Change | 4.98% |
| 1 Year Change | 23.95% |
| 3 Year Change | -39.18% |
| 5 Year Change | -93.00% |
| Change since IPO | -88.43% |
Recent News & Updates
Recent updates
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price
Dec 17
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss
Nov 26C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 05C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jul 11We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully
Jun 20Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%
Apr 18C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here
Mar 10C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Mar 04C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Shareholder Returns
| CCCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.4% | 1.2% | -0.6% |
| 1Y | 23.9% | 28.8% | 15.5% |
Return vs Industry: CCCC underperformed the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: CCCC exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| CCCC volatility | |
|---|---|
| CCCC Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCCC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CCCC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 110 | Andrew Hirsch | www.c4therapeutics.com |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
C4 Therapeutics, Inc. Fundamentals Summary
| CCCC fundamental statistics | |
|---|---|
| Market cap | US$309.32m |
| Earnings (TTM) | -US$104.99m |
| Revenue (TTM) | US$35.95m |
Is CCCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCCC income statement (TTM) | |
|---|---|
| Revenue | US$35.95m |
| Cost of Revenue | US$104.24m |
| Gross Profit | -US$68.29m |
| Other Expenses | US$36.70m |
| Earnings | -US$104.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -189.98% |
| Net Profit Margin | -292.08% |
| Debt/Equity Ratio | 39.8% |
How did CCCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/03 22:34 |
| End of Day Share Price | 2026/03/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
C4 Therapeutics, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Chi Meng Fong | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |